- Home
- PR vs MRNA Comparison
PR vs MRNA Comparison
Compare PR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PR
- MRNA
- Stock Information
- Founded
- PR 2015
- MRNA 2010
- Country
- PR United States
- MRNA United States
- Employees
- PR N/A
- MRNA N/A
- Industry
- PR Oil & Gas Production
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PR Energy
- MRNA Health Care
- Exchange
- PR Nasdaq
- MRNA Nasdaq
- Market Cap
- PR 9.5B
- MRNA 10.6B
- IPO Year
- PR 2016
- MRNA 2018
- Fundamental
- Price
- PR $12.60
- MRNA $26.56
- Analyst Decision
- PR Strong Buy
- MRNA Hold
- Analyst Count
- PR 16
- MRNA 19
- Target Price
- PR $18.53
- MRNA $48.13
- AVG Volume (30 Days)
- PR 10.2M
- MRNA 14.2M
- Earning Date
- PR 05-07-2025
- MRNA 05-01-2025
- Dividend Yield
- PR 4.76%
- MRNA N/A
- EPS Growth
- PR 39.99
- MRNA N/A
- EPS
- PR 1.62
- MRNA N/A
- Revenue
- PR $5,134,186,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- PR $8.10
- MRNA N/A
- Revenue Next Year
- PR $1.13
- MRNA $8.98
- P/E Ratio
- PR $7.77
- MRNA N/A
- Revenue Growth
- PR 37.00
- MRNA N/A
- 52 Week Low
- PR $10.01
- MRNA $23.15
- 52 Week High
- PR $16.95
- MRNA $158.82
- Technical
- Relative Strength Index (RSI)
- PR 47.05
- MRNA 50.60
- Support Level
- PR $12.51
- MRNA $25.22
- Resistance Level
- PR $13.00
- MRNA $27.15
- Average True Range (ATR)
- PR 0.31
- MRNA 1.61
- MACD
- PR -0.08
- MRNA 0.26
- Stochastic Oscillator
- PR 7.19
- MRNA 47.66
About PR Permian Resources Corporation
Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization and development of oil and liquids-rich natural gas assets. The Company's assets and operations are concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.